NEW YORK, Jan. 14, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Clovis Oncology, Inc. (NASDAQ:CLVS) between May 20, 2014 and November 13, 2015.
You are hereby notified that Levi & Korsinsky has commenced a securities class action lawsuit in the USDC for the District of Colorado. If you purchased or otherwise acquired Clovis Oncology securities between May 20, 2014 and November 13, 2015, your rights may be affected by this action. To get more information go to:
http://zlk.9nl.com/clovis-oncology-clvs
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) the New Drug Application (“NDA”) that Clovis submitted to the FDA for rociletinib contained immature data sets based on both unconfirmed response rates and confirmed response rates; (2) Clovis’ Breakthrough Therapy designation submission contained immature data sets based primarily on unconfirmed responses; (3) Clovis presented interim data publicly and at medical meetings that included a data set based primarily on unconfirmed responses; (4) as the efficacy data matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected; and (5) as a result of the foregoing, Clovis’ NDA was likely to be delayed and/or rejected by the FDA.
If you suffered a loss in Clovis Oncology you have until January 18, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
First Western Ship Transits Strait of Hormuz Since Iran War Began
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 



